AVEO Pharmaceuticals, Inc. (AVEO)

[pennyfinder]

You may wanna add this to the sticky as well:

Results demonstrated that the inhibition of GDF15 function results in the complete reversion of the phenotypic and metabolic changes associated with cancer-related anorexia-cachexia syndrome, or CACS, completely reverting body weight loss and restoring normal body composition of the tumor bearing mice. AV-380 treatment resulted in a catabolic to anabolic metabolic switch and increased food intake, energy expenditure, resting energy expenditure and physical activity. The data highlight the potential of AV-380 as a therapeutic intervention for the treatment for CACS.

Taken from: http://www.reuters.com/article/2015/04/20/ma-aveo-oncology-idUSnBw205124a+100+BSW20150420